Recombinant Human UBE2I/Ubc9 Dominant Negative, CF
Recombinant Human UBE2I/Ubc9 Dominant Negative, CF Summary
Product Specifications
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
E2-646
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Store the unopened product at -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date. |
Reconstitution Calculator
Background: UBE2I/Ubc9
Ubiquitin-conjugating Enzyme E2I (UBE2I), also known as Ubiquitin-conjugating Enzyme 9 (Ubc9), is a ubiquitously expressed protein with a predicted molecular weight of 20 kDa. Human UBE2I/Ubc9 shares 100% amino acid sequence identity with the mouse and rat orthologs. UBE2I/Ubc9 catalyzes the addition of the Ubiquitin-like protein SUMO to target proteins. SUMO is transferred from a Ubiquitin-like activating (E1) enzyme heterodimer consisting of SAE1 and UBA2 to Cys93 of UBE2I/Ubc9. In contrast to most Ubiquitin-conjugating (E2) enzymes that function in a complex with Ubiquitin ligases (E3s), UBE2I/Ubc9 can interact directly with protein substrates and may also play a role in substrate recognition. UBE2I/Ubc9 mediates the sumoylation of a variety of proteins including RanGAP1, HDAC4, and PML. Post-translational modifications of UBE2I/Ubc9, such as auto-sumoylation at Lys14 or Ser71 phosphorylation by CDC2/CDK1, alter UBE2I/Ubc9 catalytic activity and target protein recognition. UBE2I/Ubc9-dependent sumoylation reduces the levels of the stem cell marker, Nanog, implicating it in embryonic stem cell pluripotency maintenance. Sumoylation also regulates the protein levels of tumor suppressors and oncogenes, and UBE2I/Ubc9 dysregulation is thought to contribute to the pathogenesis of human cancers.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human UBE2I/Ubc9 Dominant Negative, CF
There are currently no reviews for this product. Be the first to review Recombinant Human UBE2I/Ubc9 Dominant Negative, CF and earn rewards!
Have you used Recombinant Human UBE2I/Ubc9 Dominant Negative, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
